NASDAQ:NAGE Niagen Bioscience (NAGE) Stock Price, News & Analysis $2.02 -0.06 (-2.66%) As of 03:43 PM Eastern This is a fair market value price provided by Massive. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsInsider TradesNews and TrendsOptions ChainOwnershipSEC FilingsShort Interest About Niagen Bioscience Stock (NASDAQ:NAGE) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get Niagen Bioscience alerts:Sign Up Key Stats Today's Range$1.97▼$2.0650-Day Range$2.07▼$3.1752-Week Range$1.97▼$7.11Volume664,702 shsAverage Volume829,704 shsMarket Capitalization$159.59 millionP/E Ratio16.79Dividend YieldN/APrice Target$8.50Consensus RatingBuy Company Overview Niagen Bioscience, Inc. develops and markets products based on nicotinamide riboside (NR), a form of vitamin B3 studied for its role in supporting the body’s production of NAD+. Its offerings include Tru Niagen, a consumer dietary supplement, and Niagen, a branded NR ingredient supplied to other businesses. The company also conducts and supports research on NR, NAD+ and healthy aging. It was formerly known as ChromaDex Corporation and adopted the Niagen Bioscience name in 2025. Niagen Bioscience serves consumers and commercial customers in the United States and international markets through online sales, retail and distribution channels. Rob Fried is the company’s chief executive officer.AI Generated. May Contain Errors. Read More Niagen Bioscience Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks58th Percentile Overall ScoreNAGE MarketRank™: 2.886119581065 of 5 starsNiagen Bioscience scored higher than 58% of companies evaluated by MarketBeat, and ranked 90th out of 168 stocks in the consumer staples sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion4.1 / 5Analyst RatingBuy Consensus RatingNiagen Bioscience has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 1 strong buy rating, 4 buy ratings, 1 hold rating, and no sell ratings.Upside PotentialNiagen Bioscience has a consensus price target of $8.50, representing about 328.2% upside from its current price of $1.99.Amount of Analyst CoverageNiagen Bioscience has only been the subject of 3 research reports in the past 90 days.Read more about Niagen Bioscience's stock forecast and price target. Earnings and Valuation1.3 / 5Proj. Earnings Growth-25.00% Earnings GrowthEarnings for Niagen Bioscience are expected to decrease by -25.00% in the coming year, from $0.04 to $0.03 per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Niagen Bioscience is 16.54, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 26.15.Price to Earnings Ratio vs. SectorThe P/E ratio of Niagen Bioscience is 16.54, which means that it is trading at a less expensive P/E ratio than the Consumer Staples sector average P/E ratio of about 25.86.Price to Book Value per Share RatioNiagen Bioscience has a P/B Ratio of 2.07. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities. Short Interest1.0 / 5Short Interest LevelBearish Percentage of Shares Shorted6.10% of the float of Niagen Bioscience has been sold short.Short Interest Ratio / Days to CoverNiagen Bioscience has a short interest ratio ("days to cover") of 8.91.Change versus previous monthShort interest in Niagen Bioscience has recently increased by 4.16%, indicating that investor sentiment is decreasing. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldNiagen Bioscience does not currently pay a dividend.Dividend GrowthNiagen Bioscience does not have a long track record of dividend growth. News and Social Media2.8 / 5News Sentiment0.52 News SentimentNiagen Bioscience has a news sentiment score of 0.52. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Consumer Staples companies.News Coverage This WeekMarketBeat has tracked 7 news articles for Niagen Bioscience this week, compared to 4 articles on an average week.Search Interest3 people have searched for NAGE on MarketBeat in the last 30 days. This is an increase of 200% compared to the previous 30 days.MarketBeat FollowsOnly 1 people have added Niagen Bioscience to their MarketBeat watchlist in the last 30 days. This is a decrease of 0% compared to the previous 30 days. Company Ownership0.5 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, Niagen Bioscience insiders have not sold or bought any company stock.Percentage Held by Insiders10.00% of the stock of Niagen Bioscience is held by insiders.Percentage Held by Institutions15.41% of the stock of Niagen Bioscience is held by institutions.Read more about Niagen Bioscience's insider trading history. Receive NAGE Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Niagen Bioscience and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. NAGE Stock News HeadlinesNiagen Bioscience to Present at the Sixth Annual Longevity Summit Taking Place at the Buck Institute for Research on AgingNovember 16 at 8:43 AM | marketscreener.comMNiagen Bioscience to Present at the Sixth Annual Longevity Summit Taking Place at the Buck Institute for Research on AgingNovember 16 at 8:32 AM | businesswire.comI'm handing you this one freeElon Musk doesn't own the chip powering every Tesla, every Starlink dish, and every AI satellite he builds. He licenses it from one overlooked company. That supplier just got a major catalyst. Musk filed to launch 1,000,000 satellites, a move analyst Dylan believes could drive a 100X bigger bill for this chipmaker starting December 8th.November 16 at 1:00 AM | Behind the Markets (Ad)Niagen Bioscience, Inc. (NASDAQ:NAGE) Stock Now Rated "Buy" by Wall Street BrokeragesNovember 13 at 2:15 AM | americanbankingnews.comNiagen Bioscience Expands HSA/FSA Payment Option for the Pharmaceutical-Grade Niagen™ At-Home Injection Kit through Niagen™ PlusNovember 12, 2026 | businesswire.comHead to Head Survey: Beauty Health (NASDAQ:SKIN) versus Niagen Bioscience (NASDAQ:NAGE)November 12, 2026 | americanbankingnews.comNiagen Bioscience Announces Participation in Upcoming Investor ConferencesNovember 9, 2026 | businesswire.comNiagen Bioscience (NASDAQ:NAGE) Stock Gets Price Target Reduction from Canaccord Genuity GroupNovember 9, 2026 | americanbankingnews.comSee More Headlines NAGE Stock Analysis - Frequently Asked Questions How have NAGE shares performed this year? Niagen Bioscience's stock was trading at $6.36 at the beginning of 2026. Since then, NAGE shares have decreased by 68.8% and is now trading at $1.9850. How were Niagen Bioscience's earnings last quarter? Niagen Bioscience, Inc. (NASDAQ:NAGE) announced its earnings results on Wednesday, November, 4th. The company reported ($0.01) EPS for the quarter, meeting analysts' consensus estimates of ($0.01). The firm had revenue of $27.19 million for the quarter. Niagen Bioscience had a net margin of 8.37% and a trailing twelve-month return on equity of 10.18%. Who are Niagen Bioscience's major shareholders? Niagen Bioscience's top institutional investors include SteelPeak Wealth LLC (4.49%), State Street Corp (1.37%), Marshall Wace LLP (0.59%) and Russell Investments Group Ltd. (0.10%). Insiders that own company stock include Frank L Jaksch Jr, Brianna Gerber, Ozan Pamir and Kristin Patrick. View institutional ownership trends. How do I buy shares of Niagen Bioscience? Shares of NAGE stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Niagen Bioscience own? Based on aggregate information from My MarketBeat watchlists, some other companies that Niagen Bioscience investors own include Palantir Technologies (PLTR), Advanced Micro Devices (AMD), Tesla (TSLA), NVIDIA (NVDA), Micron Technology (MU), Novavax (NVAX) and Broadcom (AVGO). Company Calendar Last Earnings11/04/2026Today11/16/2026Fiscal Year End12/31/2026Get Stock Alerts Health Indicator TradeSmith's Health IndicatorA long-term volatility-based measure designed for securities held 12 months or longer.Green: Strong and healthy uptrend with normal pullbacks.Yellow: Significant pullback but still within expected volatility.Red: Dropped beyond expected volatility; considered unhealthy. Red Zone (13m+) 1-Year History Nov 25 Feb 26 May 26 Aug 26 Nov 26 NAGE's financial health is in the Red zone, according to TradeSmith. NAGE has been in this zone for over 13 months. Industry, Sector and Symbol Stock ExchangeNASDAQ SectorConsumer Staples Industry Personal Care Products Sub-IndustryPersonal Care Products Current SymbolNASDAQ:NAGE Previous SymbolNASDAQ:NAGE CIK1386570 Webwww.niagenbioscience.com Phone(310) 388-6706Fax949-419-0294Employees117Year FoundedN/APrice Target and Rating Average Price Target for Niagen Bioscience$8.50 High Price Target$11.00 Low Price Target$6.00 Potential Upside/Downside+319.8%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage6 Analysts Profitability EPS (Trailing Twelve Months)$0.12 Trailing P/E Ratio16.88 Forward P/E Ratio67.50 P/E GrowthN/ANet Income$17.38 million Net Margins8.37% Pretax Margin9.04% Return on Equity10.18% Return on Assets7.57% Debt Debt-to-Equity RatioN/A Current Ratio5.93 Quick Ratio4.71 Sales & Book Value Annual Sales$129.42 million Price / Sales1.24 Cash Flow$0.20 per share Price / Cash Flow10.18 Book Value$0.96 per share Price / Book2.11Miscellaneous Outstanding Shares79,200,000Free Float71,277,000Market Cap$160.38 million OptionableOptionable Beta2.12 7 Best Space Stocks to Own in 2026The space race is growing fast, and you don’t have to have gotten in early on SpaceX to profit. This report shows seven space stocks you can buy today that may grow as rockets, satellites, defense, space internet, and new space technology become more important.Get This Free Report This page (NASDAQ:NAGE) was last updated on 11/16/2026 by MarketBeat.com Staff. From Our PartnersMy $247 scanner for $7Bill Poulos is cutting the price of his $247 Instant Scanner to $7 for Black Friday. It's a one-time payment t...Profits Run | SponsoredA Nasdaq drone company just landed a deal with a Philippine billionaire's groupA Nasdaq-listed drone company just signed an exclusive agreement with Prime Strategic Holdings, part of billio...The Tomorrow Investor | SponsoredWhy I'm selling my Snapback Indicator for just $7For Black Friday, Base Camp Trading's Thomas Wood is offering lifetime access to his proprietary Snapback Indi...Base Camp Trading | SponsoredEvery Starlink dish pays this stockThere's a chip inside every Tesla and Starlink dish that Elon doesn't own. He pays royalties to use it. Now...Behind the Markets | SponsoredDrop these 5 stocks before the market opens tomorrow!The Wall Street Journal called it the "$64 trillion question": is a stock market crash on the way? Weiss Ratin...Weiss Ratings | SponsoredYour Social Security check is scheduled for a 22% cutThe U.S. now borrows money just to pay interest on money it already borrowed, a pattern economists call a debt...American Alternative | SponsoredPentagon magnet restrictions take effect January 1, 2027A NASDAQ-listed company has signed a term sheet outlining a potential 75-year agreement with the U.S. Army. It...OilPrice | SponsoredThe $40 trillion number nobody won on Tuesday will touchDemocrats took the House and Senate on election night, but the $40 trillion national debt and the $1 trillion ...Vault Metal | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Niagen Bioscience, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Niagen Bioscience With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.